

MEDICAMEN Biotech Limited



Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Ref: STEX/OUTCOME/2022-23

Date: 10.02.2023

BSE Limited
Department of Corporate Services-Listing
PJ Towers, Dalal Street
Mumbai- 400001

National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E) Mumbai- 400051

Scrip Code- 531146

Symbol- MEDICAMEQ

Sub. : Outcome of Board Meeting

Dear Sir,

We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Un-Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended on December 31, 2022.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- Statement showing the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended on December 31, 2022 as **Annexure-A** and
- Limited Review Report from Rai Qimat & Associates, Chartered Accountants on the Un- Audited Financial Results (Standalone & Consolidated) as **Annexure-B**
- An Investor Presentation of the company is enclosed as **Annexure-C**

The meeting of the Board of Directors commenced on 02.30 p.m. and concluded at 03.30 p.m.

The Un-audited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended on December 31, 2022, as approved by the Board, will also be available on the Company's website www.medicamen.com.

This is for your information and records.

Thanking You.

Yours faithfully,
For Medicamen Biotech Limited


Parul Choudhary
Company Secretary
ACS44157





MEDICAMEN BIOTECH LIMITED

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, www.medicamen.com

Un-audited Standalone and Consolidated Financial Results for the Quarter and Nine Month ended as on 31st Dec' 2022

PART I		Standalone						Consolidated					
		Three Month period Ended			Nine Month Period Ended		Year Ended	Three Month period Ended			Nine Month Period Ended		Year Ended
Particulars		31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021	31.03.2022	31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021	31.03.2022
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited	Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	Income from operations												
	(a) Net Sales / Income from operations	3,411.55	3,353.22	3,264.09	10,073.57	9,269.14	11,544.52	3,558.18	3,353.22	3,264.09	10,220.20	9,269.14	11,544.52
	(b) Other Income	62.87	52.47	82.75	211.57	138.25	172.01	62.87	52.47	82.75	211.57	138.25	172.01
	Total Revenue	3,474.42	3,405.69	3,346.84	10,285.14	9,407.39	11,716.53	3,621.05	3,405.69	3,346.84	10,431.77	9,407.39	11,716.53
2	Expenses												
	a) Cost of Material Consumed	2,285.02	1,956.90	1,751.46	5,932.31	4,477.21	5,569.07	2,317.06	1,956.90	1,751.46	5,964.35	4,477.21	5,569.07
	b) Purchase of Goods Traded	-	-	-	-	-	-	-	-	-	-	-	-
	c) Changes in inventory of Finished Goods and Work in Progress	(619.22)	(299.81)	(180.79)	(919.96)	(293.02)	(333.63)	(619.22)	(299.81)	(180.79)	(919.96)	(293.02)	(333.63)
	d) Employees Benefits Expenses	493.61	491.15	361.72	1,418.94	1,065.89	1,450.19	567.12	491.15	361.72	1,492.45	1,065.89	1,450.19
	e) Finance Cost	68.19	61.60	49.29	206.51	83.67	140.06	68.19	61.60	49.29	206.51	83.67	140.06
	f) Depreciation and Amortisation Expenses	160.13	161.53	156.72	474.38	424.73	577.14	160.13	161.53	156.72	474.38	424.73	577.14
	g) Other expenses	665.51	619.42	700.83	1,904.38	2,161.40	2,503.35	705.51	620.13	700.83	1,945.09	2,161.40	2,504.29
	Total Expenses	3,053.24	2,990.79	2,839.23	9,016.56	7,919.88	9,906.18	3,198.79	2,991.50	2,839.23	9,162.82	7,919.88	9,907.11
3	Profit/(Loss) before Exceptional Items & Tax (1 - 2)	421.18	414.90	507.61	1,268.58	1,487.51	1,810.35	422.26	414.19	507.61	1,268.95	1,487.51	1,809.42
4	Exceptional Items (Commercial Tax Expenses Related to Earlier Years)	-	-	-	-	-	-	-	-	-	-	-	-
5	Profit/(Loss) before Extra Ordinary Items & Tax (3 - 4)	421.18	414.90	507.61	1,268.58	1,487.51	1,810.35	422.26	414.19	507.61	1,268.95	1,487.51	1,809.42
6	Tax Expenses												
	Current Year	78.42	86.16	155.18	262.45	344.24	397.69	78.42	86.16	155.18	262.45	344.24	397.69
	MAT Credit Entitlement	-	-	-	-	-	-	-	-	-	-	-	-
	Deferred Tax Liability	(33.18)	(32.37)	(25.42)	(89.48)	(71.90)	(77.98)	(33.18)	(32.37)	(25.42)	(89.48)	(71.90)	(77.98)
	Total Tax Expense	45.24	53.79	129.76	172.97	272.34	319.71	45.24	53.79	129.76	172.97	272.34	319.71
7	Net Profit /Loss for the period from Continuing operation (5- 6)	375.94	361.11	377.85	1,095.61	1,215.17	1,490.64	377.02	360.40	377.85	1,095.98	1,215.17	1,489.71
8	Other Comprehensive Income												
	Item that will not reclassified to Profit & Loss	-	-	-	-	-	-	-	-	-	-	-	-
9	Total Comprehensive Income net of Tax	375.94	361.11	377.85	1,095.61	1,215.17	1,490.64	377.02	360.40	377.85	1,095.98	1,215.17	1,489.71

R. B. Bhatnagar

10	Net Profit/ (loss) attributable to a) Controlling Interest b) Non Controlling Interest							376.48 0.54			1,095.44 0.54		
11	Paid up equity share capital (Rs. 10/- per share)	1,265.11	1,265.11	1,221.66	1,265.11	1,221.66	1,221.66	1,265.11	1,265.11	1,221.66	1,265.11	1,221.66	1,221.66
12	Earning Per Share (Rs.)												
	Basic	2.97	2.85	3.09	8.66	9.95	12.20	2.98	2.85	3.09	8.66	9.95	12.19
	Diluted	2.97	2.85	3.09	8.66	9.95	12.20	2.98	2.85	3.09	8.66	9.95	12.19

NOTES :

- 1 The Un-audited financial results for the quarter and nine months ended have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 10.02.2023.
- 2 This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules,2015 (Ind AS) prescribed under Section 133 of the Companies Act,2013 and other recognised accounting practices and policies to the extent applicable.
- 3 **The results are not comparable on quarterly or yearly basis as company is regularly incurring marketing expenses. The company has also recruited and placed senior human resources for the purpose of creating its own marketing network in India and francophone Africa. The company shall start reaping its benefits from next financial year.**
- 4 The company operates only in one business segment , viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- 5 The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 -"Earning per Share"
- 6 Limited review report has been carried out by the Statutory Auditors for the above period.
- 7 The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

Place : New Delhi
Dated : 10.02.2023

For & on behalf of Board of Directors
Medicamen Biotech Limited



R. Bishnoi

(Rahul Bishnoi)
Chairman

RAI QIMAT & ASSOCIATES

CHARTERED ACCOUNTANTS



LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY AND YEAR-TO-DATE STANDALONE FINANCIAL RESULTS OF MEDICAMEN BIOTECH LIMITED UNDER REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To

The Board of Directors,
Medicamen Biotech Ltd.
 1506, Chiranjiv Tower, 43,
 Nehru Place New Delhi-110019


We have reviewed the accompanying statement of unaudited financial results of M/s Medicamen Biotech Limited having its registered office situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 for the quarter and nine months ended December 31, 2022 ("the statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS - 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act"), and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 read with Regulation 63(2) of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rai Qimat & Associates
 Chartered Accountants



(Membership Number: 2013152C)
 UDIN:-23080857BGYGTL9339

Place: Gurugram
 Date: 10.02.2023

**LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY AND YEAR-TO-DATE
CONSOLIDATED FINANCIAL RESULTS OF MEDICAMEN BIOTECH LIMITED UNDER
REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE
REQUIREMENTS) REGULATIONS, 2015**

To

The Board of Directors,
Medicamen Biotech Limited
1506, Chiranjiv Tower 43,
Nehru Place, New Delhi- 110019

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of MEDICAMEN BIOTECH LIMITED ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income of its associate for the quarter and nine months ended December 31, 2022 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

5. The Statement includes the results of the Opal Pharmaceuticals Pty. Ltd and Medicamen Lifesciences Pvt. Ltd. (the "Subsidiary" Company)
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 and 7(ii) below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

RAI QIMAT & ASSOCIATES

CHARTERED ACCOUNTANTS








Our conclusion on the Statement is not modified in respect of the above matter.

For Rai Qimat & Associates
Chartered Accountants



Rai Qimat Rai Garg
Partner
(Membership Number: 4013152C)
UDIN:-23080857BGYGTM7192

Place: Gurugram
Date: 10.02.2023



Medicamen Biotech Limited

Investor Presentation Dec 2022

Business Review and Strategy



The Company has finalized a long-term exclusive marketing and distribution agreement with EURAPHARMA, a leading French company for distribution of branded pharma products in 10 Francophone countries for which company have already filed approximate 650 dossiers.

Medicamen Forays in Domestic Market with CVD



Medicamen Life Sciences products which were launched in the last quarter getting very good response in the market. So far it has launched its products in Delhi, UP, Rajasthan and now it plans to enter Haryana, Punjab and J&K.

Domestic Product Range

Diabetic



BRANDS

Sitawow 50
Sitawow 100
Sitawow M
50/1000
Sitawow
50/500

Dapica S 5/50
Dapica S 10/100
Dapica 5
Dapica 10
Dapica M 10/500
Dapica M
10/1000

Repvog .3/.5
Repvog0.3/1
Repvog0.3/2

Domestic Product Range

Hypertension

BRANDS



Affotel 20

Affotel 40

Affotel 80

Affitel AM 40/5

Affotel CT 40/6.25

Affotel CT40/12.5

Affotel Beta

Affobis 1.25

Affobis 2.5

Affobis 5

Domestic Product Range

Cardio-Vascular

BRANDS



Roswow 10

Roswow20

Roswow Gold 10

Roswow Gold 20

Roswow CV 10

Roswow A 10

Roswow 20 A

Roswow CV 20

Roswow F 10

Roswow F 20

Domestic Oncology Product Range



Domestic Oncology Product Range





m3 Medicamen Biotech Limited

Registered Office:

1506, Chiranjiv Tower, 43 Nehru Place, New Delhi- 110019

Phone: 011-47589500

E-mail: cs@medicamen.com

Website: www.medicamen.com